A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)

ID Number 15-0496

Principal Investigator(s)
Winona Tse

Department(s) or Division(s)


This study is evaluating an investigational, inhaled form of levodopa (CVT-301) in patients with Parkinson's disease who experience OFF episodes (periods when they feel their oral Parkinson's medication is no longer working). To qualify patients with Parkinson's disease should experience a minimum of 2 hours of OFF time per day while taking oral levodopa at least 4 times a day.

Contact Information
Joan Bratton
(212) 241-0279

Recruiting Patients: Yes